entertainment -WSS

entertainment

author：Wikipedia 2025-09-14 10:00:05 - browse：32

A judge ruled that Welsh Carson won't have to face antitrust allegations about its anesthesiology practice. Adobe

Welsh, Carson, Anderson & Stowe has wiggled out of the grasp of the Federal Trade Commission, but the private equity firm’s anesthesia company, U.S. Anesthesia Partners, still must face the agency’s antitrust case, a judge ruled last week.

The FTC alleged last year that the anesthesiology network monopolized markets in Texas to drive up prices, but took the unusual step of attaching Welsh Carson as a defendant with USAP. Dismissing Welsh Carson from the case was a victory for the private equity firm and, more broadly, other firms worried that the Biden administration would try to hold them responsible for anything their portfolio companies do.

But the allegations against USAP didn’t disappear, which will keep up scrutiny on companies that have made a push to acquire numerous physician groups.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

WSS

Novo Nordisk obesity pill bests Wegovy in early trial

NYU radiologists take on the challenge of expensive MRI machines

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

World's first CRISPR

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

CDC marks new Covid

Wikipedia

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Wikipedia

The cancer drug shortage isn’t new — and neither are the solutions

Anthos stroke drug appears safer than common blood thinner

In Memoriam: Notable people who died in 2023

Astellas still sees hope in its gene therapy after four deaths

DIEP, the 'gold standard' of breast reconstruction, is under threat

Anthos stroke drug appears safer than common blood thinner

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout LOUD podcast: A CRISPR milestone, biotech mixology

The high cost of giving birth even with insurance

A deep dive into Applied Therapeutics’ data, and questions on Cassava

knowledge

Wegovy, Zepbound and weight loss drugs that preserve muscle

Readout LOUD podcast: A CRISPR milestone, biotech mixology

The problem with charging patients to message their doctors

How to bring more disabled researchers into academia

Amylyx ALS drug fails large clinical trial

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

explore

knowledge

hotspot

hotspot